(Q38980628)

8 September 2017

title

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience (English)

1 reference

8 September 2017

2

E A Rozeman

1 reference

8 September 2017

6

C U Blank

1 reference

8 September 2017

A Meerveld-Eggink

1

1 reference

8 September 2017

F Lalezari

series ordinal

3

1 reference

8 September 2017

J V van Thienen

series ordinal

4

1 reference

8 September 2017

J B A G Haanen

series ordinal

5

1 reference

8 September 2017

publication date

2 February 2017

1 reference

8 September 2017

1 reference

8 September 2017

volume

28

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

862-867

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Therapeutic use of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

The B7/CD28 costimulatory family in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW692

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDW692

1 reference

8 September 2017

1 reference